BettER: Biomarker Driven Early Therapeutic Selection in Patients With HR+ HER2- Metastatic or Unresectable Breast Cancer

NCT05977036 · clinicaltrials.gov ↗

NA

Phase

RECRUITING

Status

65

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Breast Cancer
Unresectable Breast Cancer

Interventions

DEVICE: DiviTum® TKa assay
DRUG: CDK4/6 + Endocrine therapy

Sponsor

Washington University School of Medicine

Collaborators

[object Object]